Posted by Michael Wonder on 18 Oct 2021
Alnylam receives positive reimbursement recommendation from the CADTH for use of Givlaari for the treatment of acute hepatic porphyria in adults
18 October 2021 - Givlaari reduces chronic pain, improves quality of life and is the first and only therapy proven to prevent AHP attacks.
Alnylam Pharmaceuticals is pleased to announce that Givlaari (givosiran) has now received a positive recommendation for reimbursement from the CADTH.
